Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01651156
Recruitment Status : Completed
First Posted : July 26, 2012
Last Update Posted : December 30, 2013
Sponsor:
Information provided by (Responsible Party):
Otsuka Beijing Research Institute

Tracking Information
First Submitted Date  ICMJE July 24, 2012
First Posted Date  ICMJE July 26, 2012
Last Update Posted Date December 30, 2013
Study Start Date  ICMJE July 2012
Actual Primary Completion Date July 2013   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 25, 2012)
body weight (change from baseline) [ Time Frame: screening day, Day-3, Day-2, Day-1, Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day(7+3) ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 25, 2012)
Body weight (percent change from baseline) [ Time Frame: screening day, Day-3, Day-2, Day-1, Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day(7+3) ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema
Official Title  ICMJE Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Phase 3 Study to Evaluate the Efficacy and Safety of Tolvaptan in the Treatment of Patients With Cardiac Edema Based on the Conventional Therapy
Brief Summary

A randomized, double-blind, multicenter, placebo-controlled, parallel study to evaluate the efficacy and safety of Tolvaptan in the treatment of patients with cardiac edema (body fluid retention caused by congestive heart failure) based on the conventional therapy.

To evaluate the efficacy and safety of Tolvaptan 15 mg on congestive heart failure patients with body fluid retention after current diuretic treatment, after continuous treatment of 7 days' oral Tolvaptan 15mg or placebo.

Detailed Description
  • A randomized, double-blind, multicenter, placebo-controlled, parallel study
  • Study population: The congestive heart failure patients with body fluid retention after received current diuretics therapy
  • Number of patients: Patients will be randomly assigned to Tolvaptan and placebo group in 1:1 ratio, 120 patients in each group, 240 patients in total
  • Group assignment method: Tolvaptan 15 mg group: conventional therapy + Tolvaptan 15 mg Placebo group: conventional therapy + placebo
  • Administration and dosage of the study drug: Once daily, 1 tablet be taken orally after breakfast, for successive 7 days
  • Study period:
  • Screening period (4 days in minimum, 7 days in maximum), including:

Screening period: from the time the informed consent form is signed to Day -4 Observation period: 3 days before drug administration

  • Treatment period: 7 days
  • Follow up visits: Day 8 (efficacy evaluation day) and Day 7 (+3) after the last dosing
  • Post treatment survey: Day 14 (+3) after the last dosing
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Cardiac Edema
Intervention  ICMJE
  • Drug: Tolvaptan
    oral taken
    Other Name: Samsca
  • Drug: Placebo
Study Arms  ICMJE
  • Placebo Comparator: placebo
    Frequency: once per day Duration: 7days
    Intervention: Drug: Placebo
  • Experimental: Tolvaptan
    Tolvaptan tablet Frequency: once per day Duration: 7days
    Intervention: Drug: Tolvaptan
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 25, 2013)
244
Original Estimated Enrollment  ICMJE
 (submitted: July 25, 2012)
240
Actual Study Completion Date  ICMJE July 2013
Actual Primary Completion Date July 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients treated with one of the oral diuretic therapy standards (include the patients who will be treated with one of the oral diuretic therapy standards from the beginning of the observation period):

    1. Only 40 mg/day furosemide taken orally or other oral loop diuretics equivalent to 40 mg/day furosemide note 1)
    2. Combination treatment of oral loop diuretics and thiazide diuretics (no dosage limitation)
    3. Combination treatment of oral loop diuretics and aldosterone antagonists (no dosage limitation)
  • Because of the existence of excess body fluid retention, the congestive heart failure patient has at least one of these symptoms (the lower extremity edema, pulmonary congestion note 2), or jugular vein engorgement).
  • 20-85 years of age (inclusive) at the time of signing the informed consent document.
  • Gender: male or female.
  • Inpatients or patient who would be hospitalized from one day before the observation period to the end of efficacy evaluation examination after the last dosing (from Day -4 to the end of efficacy evaluation examination after the last dosing).
  • Patient who have signed the informed consent form.

Exclusion Criteria:

  • Patients equipped with circulatory assistant device.
  • Patients with any of following diseases, complications or symptoms:

    1. Suspected decreased blood volume
    2. Obstructive hypertrophic cardiomyopathy
    3. Severe aortic stenosis
    4. Hepatic coma
  • Patients with history of acute myocardial infarction within 30 days prior to screening.
  • Patients with diagnosed active myocarditis or amyloid cardiomyopathy.
  • Patients with the following diseases, complications or symptoms:

    1. Poorly controlled diabetes with a fasting glucose more than 220 mg/dL (or 12.21 mmol/L)
    2. Anuria
    3. Dysuria caused by urethral stricture, calculus or tumor
  • Patients with the following medical history of:

    1. Sustained ventricular tachycardia or ventricular fibrillation within 30 days prior to screening
    2. History of cerebrovascular accident within the past 30 days
    3. Past allergy or hypersensitive reactions to benzodiazepines (e.g. mozavaptan hydrochloride or benazepril hydrochloride)
  • Obese patients whose body mass index (BMI = body weight (kg) / height (m)2 ) is more than 35.
  • Patients with systolic pressure below 90 mmHg in supine position.
  • Patients with any of the following abnormal laboratory test parameters:

    1. Total bilirubin > 2.5 times the upper limits of normal value
    2. Serum creatine > 2.5 times the upper limits of normal value
    3. Serum Na+ > 145 mmol/L (or higher than the upper limits of normal value)
    4. Serum K+ > 5.5 mmol/L
  • Patients who unable to take medicine orally.
  • Female patients who are pregnant, breast-feeding, at childbearing ages, or with pregnancy plan.
  • Patients who participated in clinical trials of other medicine and took other study drugs within 30 days prior to sign the informed consent form.
  • Patients who participated in the clinical trial of Tolvaptan and took Tolvaptan previously.
  • Patients who have received approved Tolvaptan tablets (Trade name: Samsca) previously.
  • Except for the above, patients who were unsuitable to participate in this trial in the investigator's opinion.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 20 Years to 85 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01651156
Other Study ID Numbers  ICMJE 156-12-809-01
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Otsuka Beijing Research Institute
Study Sponsor  ICMJE Otsuka Beijing Research Institute
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Zhang Jian Fuwai Cardiovascular hospital
PRS Account Otsuka Beijing Research Institute
Verification Date December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP